Key data
| Regulation | Council Decision (EU) 2026/575, of 5 March 2026 |
|---|---|
| CELEX Reference | 32026D0575 |
| Publication | 13 March 2026 |
| Entry into force | 5 March 2026 |
| Affected parties | Pharmaceutical industry, chemical industry, health authorities and drug control authorities |
| Category | European Regulation |
| International forum | 69th session of the UN Commission on Narcotic Drugs |
| Reference frameworks | Single Convention on Narcotic Drugs of 1961 (as amended by the 1972 Protocol) and Convention on Psychotropic Substances of 1971 |
Pharmaceutical and chemical companies operating in Europe must closely monitor the 69th session of the UN Commission on Narcotic Drugs: Council Decision (EU) 2026/575, published on 13 March 2026, establishes the official position that the EU will defend in that forum to determine which substances are subject to international control.
This is not an immediate regulatory change in the catalogue of controlled substances, but rather a prior and strategic step: the EU sets its vote before the UN makes the decision. However, the consequences for the sector are direct if that decision is approved.
What does this regulation establish?
The EU Council approves the official position that its representatives will defend at the 69th session of the UN Commission on Narcotic Drugs. This commission is the international body that decides which substances are included in the lists of the two major international drug treaties:
- Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol: regulates mainly classical narcotic drugs.
- Convention on Psychotropic Substances of 1971: regulates psychotropic substances.
Both frameworks oblige signatory States to control, restrict and monitor the substances included in their lists. The inclusion of a new substance in any of these lists automatically activates a set of obligations for economic operators handling it.
The decision does not publish which specific substances are proposed for inclusion: that will be decided at the UN session itself. What Council Decision (EU) 2026/575 does is ensure that all EU Member States vote in a coordinated and aligned manner in that forum.
Economic and operational impact
The direct economic impact will depend on which substances the UN finally approves for inclusion in the lists. However, companies in the sector should already consider the operational effects that would be activated:
| Activated obligation | Description |
|---|---|
| Prior authorization | Any operation with the substance included in the list requires specific administrative authorization |
| Inventory control | Obligation to maintain detailed records of stock, movements and destination of the substance |
| Trade restrictions | Limitations on the import, export and international distribution of the substance |
| Internal regulatory adaptation | Spain will have to modify its national regulations to reflect the new inclusions approved by the UN |
For pharmaceutical and chemical companies, the operational cost of complying with these obligations can be significant: it involves reviewing manufacturing processes, supply chains, contracts with suppliers and customers, and traceability systems.
Who does it affect?
- Pharmaceutical laboratories that manufacture, research or market substances likely to be included in international lists.
- Chemical industry companies that produce or supply precursors or compounds that may be subject to control.
- Importers and exporters of active pharmaceutical substances or chemical products with potential for inclusion in lists.
- Wholesale distributors of medicines or regulated chemical products.
- Health and drug control authorities in Spain, which will have to adapt internal regulations if the UN approves new inclusions.
- Regulatory and compliance departments of any company in the sector that operates with substances within the scope of these conventions.
Practical example
A Spanish pharmaceutical laboratory that manufactures an active ingredient used in potent analgesics must monitor the 69th session of the UN Commission on Narcotic Drugs. If that session approves including that active ingredient in the lists of the 1961 Convention, the laboratory will need:
- Prior administrative authorization for each batch produced or commercial movement.
- An audited inventory control system that can be reported to the authorities.
- Review of its export contracts, as international trade restrictions will be activated immediately.
The adaptation time can be short if the company has not anticipated regulatory monitoring: changes in international lists are transferred to Spanish regulations in timeframes that do not always allow for comfortable adaptation.
What should companies do now?
- Identify the substances in your portfolio that could be affected by new inclusions in the lists of the 1961 Convention or the 1971 Convention. Review the product catalogue and active ingredients with the regulatory team.
- Monitor the outcome of the 69th session of the UN Commission on Narcotic Drugs to learn which substances have been finally included in the international lists.
- Assess the operational impact of a possible inclusion: authorization processes, inventory control systems, supply and export contracts.
- Prepare compliance procedures in advance: do not wait for Spanish regulations to formally adapt. The room for maneuver is greater if you act before the obligation becomes enforceable.
- Coordinate with the legal department or external advisor the monitoring of changes in internal Spanish regulations resulting from UN decisions.
Frequently asked questions
What specific substances are proposed for inclusion in international lists in 2026?
Council Decision (EU) 2026/575 does not publish the definitive list of substances: it establishes the official position that EU representatives will defend at the 69th session of the UN Commission on Narcotic Drugs. The specific substances will be decided at that international forum.
What obligations does a pharmaceutical company have if a substance enters the lists?
According to the regulations, the inclusion of a substance in the lists of the Single Convention of 1961 or the Convention of 1971 implies obligations of prior authorization, inventory control and international trade restrictions for those who manufacture, distribute or market it.
When does this decision enter into force and when will it affect Spanish companies?
Council Decision (EU) 2026/575 entered into force on 5 March 2026. The real impact on Spanish companies will occur if the UN approves new inclusions at the 69th session, at which point Spain will have to adapt its internal regulations.